SCYNEXIS (SCYX) - P/S ratio

P/S ratio as of February 2026 (TTM): 10.3

According to SCYNEXIS's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.8308. At the end of 2025 the company had a P/S ratio of 15.4.

P/S ratio history for SCYNEXIS from 2014 to 2025

PS ratio at the end of each year

Year	P/S ratio	Change
2025	15.4	51.88%
2024	10.1	1609.42%
2023	0.5921	-94.08%
2022	10.0	-9.84%
2021	11.1
2020	N/A	-100%
2019	733	711.62%
2018	90.3	-65.12%
2017	259	-13.42%
2016	299	-11.03%
2015	336	3905.94%
2014	8.39

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Galmed Pharmaceuticals GLMD	N/A	N/A	🇮🇱 Israel
Catalyst Pharmaceuticals CPRX	5.22	-49.42%	🇺🇸 USA
Catalent CTLT	2.61	-74.76%	🇺🇸 USA
KemPharm KMPH	19.2	85.71%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for SCYNEXIS (SCYX)

P/S ratio as of February 2026 (TTM): 10.3